Ultragenyx Pharmaceutical Inc.
RARE
Rank in Stocks
#6359
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to... Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
Share Price
$16.48
Last synced: 2026-11-20
Market Cap
$1.68B
Change (1 day)
-4.30%
Change (1 year)
-50.94%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Ultragenyx Pharmaceutical Inc. (RARE)
Category
Healthcare
EPS for Ultragenyx Pharmaceutical Inc. (RARE)
EPS as of September 2026 TTM: $-5.19
According to Ultragenyx Pharmaceutical Inc.'s latest financial reports, its current EPS (TTM) is $-5.19. At the end of 2025 the company had an EPS of $-5.83, an increase over its 2024 EPS of $-6.29.
EPS history for Ultragenyx Pharmaceutical Inc. from 2011 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-5.19 | -10.98% |
| 2025 | $-5.83 | -7.31% |
| 2024 | $-6.29 | -23.76% |
| 2023 | $-8.25 | -18.48% |
| 2022 | $-10.12 | 51.04% |
| 2021 | $-6.70 | 118.24% |
| 2020 | $-3.07 | -56.88% |
| 2019 | $-7.12 | 79.35% |
| 2018 | $-3.97 | -44.24% |
| 2017 | $-7.12 | 14.65% |
| 2016 | $-6.21 | 56.82% |
| 2015 | $-3.96 | 90.38% |
| 2014 | $-2.08 | 71.90% |
| 2013 | $-1.21 | 70.42% |
| 2012 | $-0.71 | 136.67% |
| 2011 | $-0.30 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -401.73% |
US
|
|
| $-7.08 | 36.42% |
US
|
|
| $-5.29 | 1.93% |
AU
|
|
| $21.56 | -515.41% |
NL
|
|
| $12.73 | -345.32% |
BE
|
Questions about Ultragenyx Pharmaceutical Inc.'s earnings per share (EPS)
What is Ultragenyx Pharmaceutical Inc.'s earnings per share (EPS)?
Ultragenyx Pharmaceutical Inc.'s earnings per share (EPS) over the last twelve months is $-5.19, as of Sep 2026.
What was Ultragenyx Pharmaceutical Inc.'s earnings per share (EPS) in 2025?
In 2025, Ultragenyx Pharmaceutical Inc.'s earnings per share (EPS) was $-5.83, compared with $-6.29 in 2024.
How has Ultragenyx Pharmaceutical Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Ultragenyx Pharmaceutical Inc.'s earnings per share (EPS) was highest in 2020 ($-3.07) and lowest in 2022 ($-10.12).
How does Ultragenyx Pharmaceutical Inc.'s earnings per share (EPS) compare with similar companies?
Ultragenyx Pharmaceutical Inc.'s earnings per share (EPS) ($-5.19) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.